RSVpreF vaccine candidate effective against respiratory syncytial virus
Hospital Pharmacy Europe
AUGUST 30, 2022
Pfizer’s vaccine candidate RSVpreF for respiratory syncytial virus (RSV) showed a high level of efficacy in older patients with more severe lower respiratory tract illness which was defined by three or more RSV-associated symptoms according to a press release from the company. g RSVpreF or placebo in a 1:1 ratio.
Let's personalize your content